• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Sep 12, 2022 | Press Releases

MARLBOROUGH, Mass., Sept. 12, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 11, 2022 | Press Releases

Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subjects in Q1 2023 Expects to initiate a clinical trial evaluating the...

Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting

Jun 6, 2022 | Press Releases

MARLBOROUGH, Mass., June 6, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

May 16, 2022 | Press Releases

MARLBOROUGH, Mass., May 16, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022 | Press Releases

First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass., May 12, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a...

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

May 5, 2022 | Press Releases

MARLBOROUGH, Mass., May 5, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
  • Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us